RESEARCH

Protein Kinase Inhibitor Development

"Kinome" is a depository of promising drug targets - protein kinases, which control vast diversity of molecular interactions in cell life. Indeed, numerous reports describing the discovery of new pharmaceutical substances targeting protein kinases have been published during last few years. Some of these substances are being tested in clinical trials, some of them are already on the market.

Our Department has been involved in extensive research and development of inhibitors for various protein kinases:

(thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids (TTP)

Figure 1. The binding mode of TTP22 in the CK2 active site. Hydrogen bonds are shown by the dotted lines.

To study CK2 inhibitory activity of substituted (thieno[2,3-d] pyrimidin-4-ylthio)carboxylic acids, 28 compounds of this class were synthesized and tested in vitro. The most active...

Other kinase inhibitors research:

CK2 Inhibitors

3-carboxy-4(1H)-quinolones

This CK2 inhibitors were revealed and evaluated to be a CK2 inhibitors after...

ASK1 Inhibitors

Identification of ASK1 inhibitors among the derivatives of Benzothiazol-2-yl-3-hydroxy-5-phenyl-1,5-dihydro-pyrrol-2-one

We have identified novel chemical class of ASK1 inhibitors, namely...

FGFR1 Inhibitors

Flavones

One of the first discovered in the screening of inhibitors of FGFR1 classes are...